Korninger C, Collen D
Thromb Haemost. 1981 Oct;46(3):662-5.
Human extrinsic plasminogen activator (EPA), highly purified from a melanoma cell culture fluid is inactivated in human plasma with a half-life (t 1/2) of 90-105 min. Gel filtration on Ultrogel AcA 34 of mixtures of 125I-labeled EPA and human plasma, incubated at 37 degrees C, revealed the progressive formation of two radioactive components, one with an apparent Mr of 150,000 and one eluting at the void volume. The component with an Mr of 150,000 was identified as consisting at least in part of EPA-alpha 2-antiplasmin complex since: 1) it reacted with antibodies against alpha 2-antiplasmin, but not with antibodies against the other known plasma protease inhibitors, and 2) formation of this component was strongly reduced in plasma specifically depleted in alpha 2-antiplasmin or when the active site of EPA was blocked. The component eluting at the void volume was identified as consisting at least in part of EPA-alpha 2-macroglobulin complex since: 1) it only reacted with antibodies against these two proteins and 2) was not formed in plasma depleted in alpha 2-macroglobulin or when the active site of EPA was blocked. In purified systems alpha 2-antiplasmin inhibited one-chain EPA with a rate constant of 60 M-1s-1 and two-chain EPA with a rate constant of 130 M-1s-1, which corresponds to a t 1/2 in plasma of 180 min or 90 min, respectively. alpha 2-Macroglobulin inhibited one-chain EPA with a rate constant of 15 M-1s-1 and two-chain EPA with a rate constant of 30 M-1s-1, which corresponds to a t 1/2 in plasma of 4 or 2 hrs. All these findings taken together indicate that EPA is slowly neutralized in human plasma primarily by alpha 2-antiplasmin and to a lesser extent by alpha 2-macroglobulin. There appears to be no specific inhibitor in human plasma, which would inactivate EPA either rapidly or to a significant extent.
从黑色素瘤细胞培养液中高度纯化得到的人外源性纤溶酶原激活剂(EPA),在人血浆中会失活,半衰期(t1/2)为90 - 105分钟。对125I标记的EPA与人类血浆的混合物在37℃孵育后,在Ultrogel AcA 34上进行凝胶过滤,结果显示逐渐形成了两种放射性成分,一种表观分子量为150,000,另一种在空体积处洗脱。表观分子量为150,000的成分至少部分被鉴定为EPA-α2-抗纤溶酶复合物,原因如下:1)它能与抗α2-抗纤溶酶的抗体发生反应,但不与针对其他已知血浆蛋白酶抑制剂的抗体反应;2)在α2-抗纤溶酶特异性耗尽的血浆中,或者当EPA的活性位点被阻断时,该成分的形成会显著减少。在空体积处洗脱的成分至少部分被鉴定为EPA-α2-巨球蛋白复合物,原因如下:1)它仅与针对这两种蛋白质的抗体发生反应;2)在α2-巨球蛋白耗尽的血浆中,或者当EPA的活性位点被阻断时,该成分不会形成。在纯化系统中,α2-抗纤溶酶抑制单链EPA的速率常数为60 M-1s-1,抑制双链EPA的速率常数为130 M-1s-1,这分别对应于在血浆中的半衰期为180分钟或90分钟。α2-巨球蛋白抑制单链EPA的速率常数为15 M-1s-1,抑制双链EPA的速率常数为30 M-1s-1,这分别对应于在血浆中的半衰期为4小时或2小时。综合所有这些发现表明,EPA在人血浆中主要被α2-抗纤溶酶缓慢中和,其次是被α2-巨球蛋白中和。人血浆中似乎不存在能快速或显著使EPA失活的特异性抑制剂。